2013

Saint Luke’s Hospital unveils Neuroscience Institute

Friday, January 11, 2013

Designed to serve as one of the preeminent neuroscience centers in the country, the Saint Luke’s Neuroscience Institute (SLNI) tower officially opened January 9 at Saint Luke’s Hospital. The new facility, specializing in streamlined care for neurological disorders, offers the Kansas City community and the entire region a dedicated neuroscience hospital, created to lead the way in research, medical advancements, patient outcomes, comfort and quality of care.

[Read More]

Altravax awarded $1.2M to advance dengue vaccine and hep B therapeutic

Friday, January 11, 2013

Altravax, a privately held biopharmaceutical company based in Fargo, N.D., has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH’s National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax’s two lead commercial programs.

[Read More]

European Medicines Agency to focus on efficiency, transparency in 2013

Thursday, January 10, 2013

The European Medicines Agency’s management board has adopted the agency’s work program and budget for 2013, with priorities continuing to be ensuring assessment activities are conducted to the highest scientific levels, increasing efficiency in its activities and developing initiatives for greater transparency and communication with stakeholders.

[Read More]